At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
Cingaldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint
In Brief
A clinical study evaluating Cingal for Osteoarthritis, Hip. Completed, enrolled 25 participants across 4 sites in 2 countries.
Detailed Summary
This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal used for the symptomatic relief of osteoarthritis in the hip joint.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Hip
CountriesCzechia, Poland
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartJan 2021
Primary CompletionSep 2021
TodayJul 2026
First PostedNov 23, 2020
Enrollment StartJan 16, 2021
Primary CompletionSep 10, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.6 years ago
Interventions
Cingaldevice
Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).